Read by QxMD icon Read


shared collection
12 papers 0 to 25 followers
Lesley J Scott
Tetravalent, live-attenuated, dengue vaccine (Dengvaxia(®); CYD-TDV) is the first vaccine approved for the prevention of dengue disease caused by dengue virus (DENV) serotypes 1-4 in individuals aged 9-45 or 9-60 years living in high dengue endemic areas. This narrative review discusses the immunogenicity, protective efficacy, reactogenicity and safety of CYD-TDV in the prevention of dengue disease. In Latin American and Asian phase 3 trials in children and adolescents (n > 30,000), the recommended three-dose CYD-TDV regimen was efficacious in preventing virologically-confirmed dengue (VCD) during the period from 28 days after the last dose (month 13) to month 25, meeting the primary endpoint criteria...
September 2016: Drugs
Thomas J Hladish, Carl A B Pearson, Dennis L Chao, Diana Patricia Rojas, Gabriel L Recchia, Héctor Gómez-Dantés, M Elizabeth Halloran, Juliet R C Pulliam, Ira M Longini
Dengue vaccines will soon provide a new tool for reducing dengue disease, but the effectiveness of widespread vaccination campaigns has not yet been determined. We developed an agent-based dengue model representing movement of and transmission dynamics among people and mosquitoes in Yucatán, Mexico, and simulated various vaccine scenarios to evaluate effectiveness under those conditions. This model includes detailed spatial representation of the Yucatán population, including the location and movement of 1...
May 2016: PLoS Neglected Tropical Diseases
Sumathy Velumani, Ying Xiu Toh, Shobana Balasingam, Sophia Archuleta, Yee Sin Leo, Victor C Gan, Tun Linn Thein, Annelies Wilder-Smith, Katja Fink
Globally, dengue virus (DENV) is one of the most widespread vector-borne viruses. Dengue disease affects populations in endemic areas and, increasingly, tourists who travel to these countries, but there is currently no approved vaccine for dengue. A phase 3 efficacy trial with Sanofi-Pasteur's recombinant, live-attenuated, tetravalent dengue vaccine (CYD-TDV) conducted in South East Asia showed an overall efficacy of 56% against virologically confirmed dengue infections of any severity and any of the 4 serotypes, but the long-term protection of the vaccine has yet to be demonstrated...
May 3, 2016: Human Vaccines & Immunotherapeutics
J Martin, L Hermida
Dengue is an increasing public health problem worldwide, with the four serotypes of the virus infecting over 390 million people annually. There is no specific treatment or antiviral drug for dengue, and prevention is largely limited to controlling the mosquito vectors or disrupting the human-vector contact. Despite the considerable progress made in recent years, an effective vaccine against the virus is not yet available. The development of a dengue vaccine has been hampered by many unique challenges, including the need to ensure the absence of vaccine-induced enhanced severity of disease...
March 2016: Acta Virologica
Usa Thisyakorn, Chule Thisyakorn
The uniqueness of the dengue viruses (DENVs) and the spectrum of disease resulting from infection have made dengue vaccine development difficult. Several vaccine candidates are currently being evaluated in clinical studies. The candidate currently at the most advanced clinical development stage, a live-attenuated tetravalent vaccine based on the chimeric yellow fever-dengue virus (CYD-TDV), has progressed to Phase 3 efficacy studies. Several other live-attenuated vaccines, as well as subunit, DNA, and purified inactivated vaccine candidates are at earlier stages of clinical development...
2015: Southeast Asian Journal of Tropical Medicine and Public Health
Sathyamangalam Swaminathan, Gaurav Batra, Navin Khanna
IMPORTANCE OF THE FIELD: Dengue is a significant public health problem transcending geographical boundaries to place nearly 50% of the global population at risk. A vaccine to prevent dengue is an unmet need that should be addressed urgently. AREAS COVERED IN THE REVIEW: A brief introduction to dengue and a detailed review of the classical and modern approaches being undertaken currently to develop dengue vaccines described in recent patent literature, highlighting the inherent hurdles and challenges...
June 2010: Expert Opinion on Therapeutic Patents
Anna P Durbin, Beth D Kirkpatrick, Kristen K Pierce, Marya P Carmolli, Cecilia M Tibery, Palmtama L Grier, Noreen Hynes, Kari Opert, Adrienne P Jarvis, Beulah P Sabundayo, Benjamin D McElvany, Eli A Sendra, Catherine J Larsson, Matthew Jo, Janece M Lovchik, Catherine J Luke, Mary C Walsh, Ellen A Fraser, Kanta Subbarao, Stephen S Whitehead
UNLABELLED: The ideal dengue vaccine will provide protection against all serotypes of dengue virus and will be economical and uncomplicated in its administration. To determine the ability of a single dose of the live attenuated tetravalent dengue vaccine TV003 to induce a suitable neutralizing antibody response, a placebo-controlled clinical trial was performed in 48 healthy adults who received 2 doses of vaccine or placebo administered 12 months apart. Evaluation of safety, vaccine viremia, and neutralizing antibody response after each dose indicated that the first dose of vaccine was capable of preventing infection with the second dose, thus indicating that multiple doses are unnecessary...
September 15, 2016: Journal of Infectious Diseases
Ana Carvalho, Rebecca Van Roy, Jon Andrus
Dengue vaccine introduction will likely occur soon. However, little has been published on international dengue vaccine communication and advocacy. More effort at the international level is required to review, unify and strategically disseminate dengue vaccine knowledge to endemic countries' decision makers and potential donors. Waiting to plan for the introduction of new vaccines until licensure may delay access in developing countries. Concerted efforts to communicate and advocate for vaccines prior to licensure are likely challenged by unknowns of the use of dengue vaccines and the disease, including uncertainties of vaccine impact, vaccine access and dengue's complex pathogenesis and epidemiology...
2016: Expert Review of Vaccines
Jacqueline Kyungah Lim, Yong-Seok Lee, Annelies Wilder-Smith, Georges Thiry, Richard Mahoney, In-Kyu Yoon
Dengue is a public health problem in the tropics and subtropics. There are several vaccine candidates in clinical development. However, there may be gaps in the new vaccine introduction after vaccine licensure before it becomes available in developing countries. In anticipation of the first dengue vaccine candidate to be licensed, Dengue Vaccine Initiative (DVI) and, its predecessor, Pediatric Dengue Vaccine Initiative (PDVI) have been working on points for consideration to accelerate evidence-based dengue vaccine introduction, once a vaccine becomes available...
2016: Expert Review of Vaccines
Bruno Guy, Olivier Briand, Jean Lang, Melanie Saville, Nicholas Jackson
Sanofi Pasteur has developed a recombinant, live-attenuated, tetravalent dengue vaccine (CYD-TDV) that is in late-stage development. The present review summarizes the different steps in the development of this dengue vaccine, with a particular focus on the clinical data from three efficacy trials, which includes one proof-of-concept phase IIb (NCT00842530) and two pivotal phase III efficacy trials (NCT01373281 and NCT01374516). Earlier studies showed that the CYD-TDV candidate had a satisfactory safety profile and was immunogenic across the four vaccine serotypes in both in vitro and in vivo preclinical tests, as well as in initial phase I to phase II clinical trials in both flavivirus-naïve and seropositive individuals...
December 10, 2015: Vaccine
Sri Rezeki Hadinegoro, Jose Luis Arredondo-García, Maria Rosario Capeding, Carmen Deseda, Tawee Chotpitayasunondh, Reynaldo Dietze, H I Hj Muhammad Ismail, Humberto Reynales, Kriengsak Limkittikul, Doris Maribel Rivera-Medina, Huu Ngoc Tran, Alain Bouckenooghe, Danaya Chansinghakul, Margarita Cortés, Karen Fanouillere, Remi Forrat, Carina Frago, Sophia Gailhardou, Nicholas Jackson, Fernando Noriega, Eric Plennevaux, T Anh Wartel, Betzana Zambrano, Melanie Saville
BACKGROUND: A candidate tetravalent dengue vaccine is being assessed in three clinical trials involving more than 35,000 children between the ages of 2 and 16 years in Asian-Pacific and Latin American countries. We report the results of long-term follow-up interim analyses and integrated efficacy analyses. METHODS: We are assessing the incidence of hospitalization for virologically confirmed dengue as a surrogate safety end point during follow-up in years 3 to 6 of two phase 3 trials, CYD14 and CYD15, and a phase 2b trial, CYD23/57...
September 24, 2015: New England Journal of Medicine
Vivaldo G da Costa, Ariany C Marques-Silva, Vitor G Floriano, Marcos L Moreli
The World Health Organization has stipulated a target: reduce the mortality rate caused by dengue disease by 50% until 2020. Most likely, this goal can be achieved by means of a dengue vaccine. Accordingly, the recombinant and tetravalent dengue vaccine (CYD-TDV), developed by the Sanofi Pasteur Group, is in an advanced stage of human testing. Although there are multiple randomized, placebo-controlled trials evaluating the CYD-TDV, individual results may have little power to identify differences between the populations studied...
September 3, 2014: Vaccine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"